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The prospect of phasing diffraction data sets ‘de novo’ for
proteins with previously unseen folds is appealing but largely
untested. In a ﬁrst systematic exploration of phasing with
Rosetta de novo models, it is shown that all-atom reﬁnement
of coarse-grained models signiﬁcantly improves both the
model quality and performance in molecular replacement with
the Phaser software. 15 new cases of diffraction data sets that
are unambiguously phased with de novo models are presented.
These diffraction data sets represent nine space groups and
span a large range of solvent contents (33–79%) and
asymmetric unit copy numbers (1–4). No correlation is
observed between the ease of phasing and the solvent content
or asymmetric unit copy number. Instead, a weak correlation
is found with the length of the modeled protein: larger
proteins required somewhat less accurate models to give
successful molecular replacement. Overall, the results of this
survey suggest that de novo models can phase diffraction data
for approximately one sixth of proteins with sizes of 100
residues or less. However, for many of these cases, ‘de novo
phasing with de novo models’ requires signiﬁcant investment
of computational power, much greater than 10
3 CPU days per
target. Improvements in conformational search methods will
be necessary if molecular replacement with de novo models is
to become a practical tool for targets without homology to
previously solved protein structures.
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1. Introduction
Molecular replacement has become one of the most widely
used tools for solving the crystallographic phase problem for
protein diffraction data sets. With widely available software,
rapid phasing is possible if models with structural similarity to
the crystallized protein are available (Blow & Rossmann,
1961). As the data bank of solved protein crystal structures
continues to expand and as comparative modeling methods
become increasingly sophisticated (Schwarzenbacher et al.,
2004; Giorgetti et al., 2005; Raimondo et al., 2007; Qian et al.,
2007), the use of molecular replacement is likely to continue to
grow.
In recent years, a new frontier for molecular replacement
has come into view. A number of diffraction data sets have
now been phased ‘de novo’, i.e. in the absence of evolutionary
information from structural homologs or experimental data
from methods such as NMR. For a tetrameric coiled coil
(Howard et al., 2007) or a heptameric membrane helix
assembly (Strop et al., 2007), the stereotypical conformation of
helices and assumptions regarding the internal symmetry ofthe complexes have been sufﬁcient to produce successful
molecular-replacement templates. [There has also been a long
history of phasing nucleic acid crystals with ideal double
helices; see, for example, Szep et al. (2003).] For the more
general case of an asymmetric protein, our group, in colla-
boration with the developers of Phaser (McCoy, 2007), has
recently presented an example in which the diffraction data
for target T0283 in the 2006 Critical Assessment of Structure
Prediction were phased by a de novo blind model produced
with the Rosetta high-resolution prediction methodology
(Qian et al., 2007). These examples suggest that de novo
modeling is beginning to pass a quite stringent test for accu-
racy, as was eloquently anticipated by Petsko eight years ago
(Petsko, 2000). Perhaps more importantly, a template-free
approach holds practical promise for assisting crystallographic
phasing for the substantial number of targets for which
structural homologues or other experimental data are not
available. However, the number of existing examples remains
anecdotal; a much larger set of successful de novo phasing
solutions is required to delineate the current capabilities and
limitations of the method.
In this study, we systematically explore three aspects of this
molecular-replacement approach, which we have termed ‘de
novo phasing with de novo models’. We ﬁrst test whether all-
atom reﬁnement of initial low-resolution models is critical for
successful molecular replacement, carrying out a benchmark
on 30 diffraction data sets. Secondly, we test whether bringing
to bear a large amount of computational power (well over
1000 CPU days per target) increases the rate of successful
phasing with Rosetta de novo models. Finally, we inspect these
benchmark results to determine whether particular para-
meters such as solvent content and the number of copies in the
asymmetric unit render diffraction data sets more amenable or
more difﬁcult for molecular replacement. With more than a
dozen new examples of successful de novo phasing, this study
presents a ﬁrst portrait of what can and cannot be achieved
when combining state-of-the-art de novo structure modeling
and state-of-the-art molecular-replacement methods.
2. Is all-atom refinement necessary for de novo
phasing?
The critical advance that has enabled blind de novo methods
to produce high-resolution predictions (better than 2 A ˚ C

r.m.s.d. from the crystal structure) has been the reﬁnement of
initial coarse-grained models in the context of a physically
realistic all-atom force ﬁeld (Rohl et al., 2004; Kuhlman et al.,
2003; Bradley et al., 2005; Das et al., 2007). [We note here that
‘reﬁnement’ refers to the optimization of model conforma-
tions in the absence of experimental data and should not be
confused with reﬁnement of coordinates based on diffraction
data, as occurs during crystallographic structure determina-
tion (Murshudov et al., 1997).] The Rosetta all-atom reﬁne-
ment method is computationally expensive. The sharp
penalties associated with atom–atom steric clashes require the
extensive minimization of all the protein degrees of freedom
after each exploratory perturbation of the side-chain or
backbone conformation. With current processors, the Rosetta
algorithm requires on the order of an hour to reﬁne a protein
model with a length of 100 residues, nearly twice as long as the
initial low-resolution conformational search (Das et al., 2007).
On one hand, this expensive procedure produces very little
change in the structure, with the protein backbone typically
shifting by less than 2 A ˚ . On the other hand, the ﬁnal all-atom
score is typically far better at discriminating near-native
conformations from non-native models than low-resolution
force ﬁelds and is thus critical for selecting a small number of
blind high-resolution predictions from pools of thousands of
low-resolution models. For the CASP7 blind trials in 2006, de
novo predictions from our group required the use of a
distributed network of tens of thousands of volunteer
computers, Rosetta@home, to carry out all-atom reﬁnement
on the models generated for nearly 100 targets (Das et al.,
2007).
However, for applications to the crystallographic phase
problem such reﬁnement may not be necessary. Automated
robust molecular-replacement software packages such as
Phaser permit the screening of thousands of models in a single
night on current computer clusters. It may be that models
containing only the N, C
,C
, C and O heavy atoms produced
by the ﬁrst low-resolution conformational search of Rosetta
can be selected based on their performance in likelihood-
based molecular replacement, without a computationally
expensive Rosetta all-atom reﬁnement occurring in between.
For example, while the diffraction data for CASP target T0283
could be phased with a high-resolution blind prediction (Qian
et al., 2007), we subsequently discovered that automated and
nearly complete rebuilding of the structure could also be
achieved by molecular replacement with a coarse-grained low-
resolution model, albeit one selected based on knowledge of
the crystal structure (unpublished results). Can low-resolution
computationally inexpensive models be used in general for
molecular replacement?
To investigate this question, we carried out a benchmark of
phasing with low-resolution and high-resolution models,
focusing on sequences of length 100 residues or less from an
in-house de novo modeling benchmark. For each of these
sequences, the structures of targets and of proteins homo-
logous in sequence or structure were removed from the
fragment libraries used to generate the Rosetta models
(Bradley et al., 2005), thus mimicking a real-world trial in
which templates would not be available for a new protein
target. The set of benchmark sequences was pre-ﬁltered based
on small-scale low-resolution modeling runs indicating that
Rosetta conformational sampling could produce models
within 3 A ˚ C
 r.m.s.d. from experimental structures, with the
hope that aggressive sampling and high-resolution reﬁnement
would yield structures within the 1.5 A ˚ C
 r.m.s.d. accuracy
bound that is widely considered to be necessary for accurate
molecular replacement (Chen et al., 2000). (Targets for which
Rosetta cannot currently achieve this accuracy were assumed
to be beyond the scope of successful molecular replacement
and remain challenges for improving Rosetta’s low-resolution
conformational sampling.) For 16 of the 32 considered
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Protein Data Bank for crystals containing the protein
sequence of interest and no other macromolecule chains. For
several of the sequences, crystals in different space groups
were available and the diffraction data with the highest
resolution available for each space group were chosen. A total
of 30 diffraction data sets were assembled into a ﬁnal bench-
mark for de novo phasing (Table 1). For each sequence, we
invested 100 CPU days per target for low-resolution modeling
and 100 CPU days per target for high-resolution modeling.
This computational effort is on a scale that is feasible with
computer clusters available at most research institutions and
leads to 1  10
4 to 4  10
4 low-resolution models for each
sequence. Fewer high-resolution models (3  10
3 to 1  10
4)
are obtained with the same computational power owing to the
expense of all-atom reﬁnement. The modeling was carried out
on Rosetta@home (v.5.96).
Molecular-replacement trials were carried out with Phaser
1.3.3, available as part of the CCP4 software suite (McCoy,
2007), using the default Phaser parameters and inputting a
putative C
 r.m.s.d. uncertainty of 1.5 A ˚ for each model. To
save on computational expense at this phasing step, we
targeted a subset of 200 models ﬁltered with the best energies
and as a control a group of 200 randomly chosen models.
The criteria we used to determine whether the molecular-
replacement solution was unambiguous and accurate were
twofold. Firstly, the Phaser translation-function Z score (TFZ)
of the model was required to be ﬁve standard deviations
beyond the mean TFZ score seen in the randomly chosen
models; a universal absolute cutoff for TFZ did not seem to be
appropriate because some diffraction data sets showed
uniformly depressed or elevated TFZ values for random
models. For the P1 space group, the rotation-function Z score
(RFZ) was monitored instead of TFZ. If more than one
molecule was present in the asymmetric unit, iterative and
automated Phaser searches for all the molecules were carried
out using the software’s default settings and the TFZ score for
the ﬁnal model was monitored. Secondly, the rotational
research papers
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Table 1
De novo phasing benchmark.
Minimum F1A ˚ of an unambiguous Phaser solution†
Structure
factors
Model
sequence‡
Space
group
No. of
residues
in model
No. of
molecules
in ASU
Solvent
content
(%)
No. of
models,
100 CPU
days§
No. of
models,
large-scale}
Low-resolution
models,
100 CPU days††
All-atom
models,
100 CPU
days††
All-atom
models,
large-scale††
Models,
native
constraints‡‡ Overall§§
1be7 1bq9 H3 51 1 43 3.5  10
5 1.7  10
7 — — — 0.882 0.882
1bq9 1bq9 P212121 51 1 43 3.5  10
5 1.7  10
7 — — — 0.627 0.627
2igd 1pgx P212121 55 1 46 2.7  10
5 4.2  10
5 — — 0.745 0.891 0.709
5cro 5cro H32 55 4 70 2.6  10
5 7.4  10
5 — — 0.927 0.982 0.709
1hz5 1hz6 P3221 61 2 72 2.3  10
5 7.3  10
5 — 0.541 0.656 0.787 0.541
1hz6 1hz6 P212121 61 3 59 2.3  10
5 7.3  10
5 — 0.672 0.689 0.836 0.639
1a32 1a32 P212121 65 1 41 2.8  10
5 2.8  10
5 — 0.754 0.708 0.800 0.677
1ctf 1ctf P43212 68 1 47 2.4  10
5 3.2  10
5 — — — 0.882 0.515
1aar 1ubi P1 71 2 35 2.0  10
5 5.4  10
7 — — — — 1.000
1f9j 1ubi I4122 71 2 60 2.0  10
5 5.4  10
7 — — — — 0.901
1ubq 1ubi P212121 71 1 33 2.0  10
5 5.4  10
7 — — 0.690 0.662 0.549
2fcq 1ubi P4332 71 2 58 2.0  10
5 5.4  10
7 — — — — 0.915
2ojr 1ubi P3221 71 1 73 2.0  10
5 5.4  10
7 — — — 0.549 0.549
1dt4 1dtj P42212 74 1 54 2.8  10
5 4.9  10
5 0.649 0.622 0.500 0.635 0.419
1dtj 1dtj C2 74 4 60 2.8  10
5 4.9  10
5 — 0.635 0.716 0.811 0.635
1ig5 1ig5 P43212 75 1 43 2.3  10
5 8.3  10
6 — — — 0.307 0.307
1cm3 1opd P21 85 1 28 2.3  10
5 8.4  10
6 — — — 0.753 0.459
1opd 1opd P1 85 1 33 2.3  10
5 8.4  10
6 — — — 0.800 0.800
1a19 1a19 I41 89 2 49 1.7  10
5 7.0  10
6 — — — 0.494 0.494
2hxx 1a19 C2 89 2 46 1.7  10
5 7.0  10
6 — — — 0.674 0.674
1mb1 1bm8 P41212 99 1 51 1.6  10
5 9.2  10
5 — — — — 0.747
2hsh 1aiu C2 105 1 35 1.5  10
5 4.4  10
5 — — 0.400 0.600 0.400
1m6t 256b C2221 106 1 43 1.8  10
5 1.5  10
5 — 0.453 0.443 0.491 0.283
256b 256b P1 106 2 45 1.8  10
5 1.5  10
5 — — 0.660 0.594 0.585
2bc5 256b P212121 106 4 42 1.8  10
5 1.5  10
5 — 0.538 — 0.689 0.538
1elw 1elw P41 117 2 47 1.5  10
5 1.1  10
5 — 0.453 0.521 0.897 0.436
1ab6 2chf P31 128 2 57 1.2  10
5 3.5  10
6 — — 0.508 0.398 0.398
2fka 2chf F432 128 1 79 1.2  10
5 3.5  10
6 — 0.430 0.359 0.367 0.313
3chy 2chf P212121 128 1 41 1.2  10
5 3.5  10
6 — — — 0.492 0.320
6chy 2chf P212121 128 2 43 1.2  10
5 3.5  10
6 — — 0.398 0.422 0.398
† F1A ˚ is a measure of model accuracy: the fraction of C
 atoms within 1 A ˚ of the crystal structure of the modeled sequence. A dash (—) indicates that no models were found within the
speciﬁed subset that gave an unambiguous Phaser solution. ‡ The Rosetta-modeled sequences were taken from an in-house curated benchmark used to test de novo modeling; in some
cases the sequence does not include terminal segments (typically loops) or particular mutations present in the crystallized sequence. § Results of 100 CPU days per target without all-
atom reﬁnement, as is typically achievable by a state-of-the-art computer cluster; application of the same computational effort but including all-atom reﬁnement led to pools of
approximately one third the size. } Results from 10
4–10
5 CPU days per target, with all-atom reﬁnement, as is achievable with distributed computing. †† Out of each pool of de novo
models, the 200 models with best energies were tested for molecular replacement. ‡‡ Out of pools of approximately 50 000 models produced with the de novo method constrained with
coarse native information for the backbone torsion angles, 40 models with the lowest C
 r.m.s.d. were tested for molecular replacement. §§ Minimum F1A ˚ that led to an unambiguous
Phaser solution among all models tested in this study, including an additional 50 models with the lowest C
 r.m.s.d. to the crystal structure for each set (results not separately shown).
These values are used as estimates of the ‘ease of phasing’ for each data set (see Table 2).research papers
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Figure 1
New examples of successful molecular replacement with Rosetta de novo models. (a)–(c) and (g)–(i) display correlations of Phaser translation-function
Z score (TFZ) with model accuracy (the fraction of C
 atoms within 1 A ˚ of the crystal structure). For each target, the displayed subsets are 200 randomly
selected all-atom reﬁned models (black) and 200 models with lowest energy from the 100 CPU-day low-resolution set (gray), from the 100 CPU-day all-
atom reﬁned set (magenta) and from the large-scale all-atom reﬁned set (red). The solid line and dashed line display the mean TFZ scores and a cutoff
value ﬁve standard deviations above the mean TFZ, respectively, in the randomly chosen models. Larger open circles indicate Phaser solutions with
correct orientations in the unit cell (see text). (d)–(f) and (j)–(l) give overlays corresponding to each plot in (a)–(c) and (g)–(i), respectively, of the least
accurate model that passes the TFZ cutoff value (red, partly transparent), nearly complete models built by ARP/wARP after molecular replacement
(green) and the crystal structure (blue). In some cases, the modeled sequence did not include terminal segments present in the crystal structures [see red
structures in (d)–(f) and (j)–(l)].orientation of the model needed to be correct; we required
that at least half of the C
 atoms in the model were positioned
within 2 A ˚ of a C
 atom in the native structure after trans-
lating the centers of mass to the origin and applying the
different rotation matrices associated with the crystal’s point
group.
The results of this benchmark, given in Table 1, strongly
indicate the importance of all-atom reﬁnement in carrying out
molecular replacement with de novo models. Out of 30 data
sets, low-resolution models passing these criteria for un-
ambiguous phasing were found in only one case. The rate of
successful molecular replacement was signiﬁcantly greater
among the smaller but more accurate pools of high-resolution
all-atom-reﬁned models, with nine cases giving success. In the
21 cases in which phasing was not achieved, was success
precluded by limits in the applied conformational search or
other properties of the protein sequence or the diffraction
data set? To derive a broader understanding of the factors that
affect the success of de novo phasing, we sought a larger and
more diverse set of diffraction data sets phased by de novo
models, as described in the following.
3. Large-scale tests
In de novo modeling, increasing the amount of computational
power enables larger scale conformational searches and
higher resolution models that can be selected based on their
all-atom energies (Das et al., 2007). For the protein sequences
tested here, very large collections of all-atom reﬁned models
were already available from previous benchmark studies on
Rosetta@home. With 10
4–10
5 CPU days invested in each
target, which is more than one hundred-fold greater compu-
tational power than in the tests above, between 1  10
5 and
5  10
7 models could be generated for each target. As above,
to save computational time for molecular replacement (which
has not been implemented for distributed computing), Phaser
runs were carried out on 200 models with the lowest all-atom
energy and 200 randomly chosen models.
With the application of greatly enhanced computational
power, the number of diffraction data sets unambiguously
phased by de novo models increased signiﬁcantly from nine to
15. Examples of these phasing successes are shown in Fig. 1.
Furthermore, for each of the all-atom reﬁned cases, we put the
models with the highest Phaser TFZ scores through ﬂex-
wARP (Cohen et al., 2008), the latest version of the automated
coordinate-building package ARP/wARP, using default
parameters (Perrakis et al., 1999). This widely used method
can produce complete and accurate models if the quality of
the beginning molecular-replacement solution was high
(Cohen et al., 2008). In each of the cases investigated, ﬂex-
wARP was able to successfully and accurately build and
sequence-assign the majority of the protein residues (see Fig.
1). The data sets that were successfully phased span the full
spectrum of crystallographic space groups, from the most
common, P212121 (Figs. 1a and 1b), to rarer groups such as
H32 (Fig. 1g) to groups with fewer symmetry operators such as
P1( F i g .1 h). Furthermore, crystals with solvent contents at the
lowest end of the probed diffraction data sets (e.g. 33%; see
Fig. 1a) were phased. Finally, crystals with multiple copies in
the asymmetric unit appeared to pose no fundamental barrier
to Phaser’s automated multi-copy search (Figs. 1g–1i); use of a
newer version of Phaser that takes into account noncrys-
tallographic symmetry, which is a frequent property of protein
crystals (Kleywegt & Read, 1997), may even further enhance
the success rate.
Finally, we investigated potential causes for the failure of
molecular replacement for the remaining 15 of the 30
diffraction data sets. On one hand, these cases may have been
refractory to phasing by de novo models owing to artefacts in
the Rosetta all-atom force ﬁeld, e.g. its tendency to extend
surface side chains into solution or its use of ideal bond
lengths and bond angles. On the other hand, de novo phasing
may have failed simply as a consequence of the unavailability
of sufﬁciently accurate structures in the tested pools of
Rosetta models
1. To test these hypotheses, we carried out
phasing runs on a more native-like set of Rosetta all-atom
reﬁned models that had been prepared with the de novo
protocol constrained with information derived from the native
structure. Additional constraints were imposed to favor the
native assignment of each residue’s backbone torsions in
coarse regions of the Ramachandran plot (Blum et al., 2007;
D. Kim & D. Baker, manuscript in preparation). From the
approximately 50 000 models in each of these sets, a subset of
the 40 lowest C
 r.m.s.d. models were subjected to Phaser
molecular replacement. With this more native-like population
of models, 26 of the 30 diffraction data sets could be phased
successfully (Table 1). The four remaining data sets could be
phased by models generated by all-atom reﬁnement of the
research papers
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Table 2
Correlation of different crystallographic parameters with the minimal
accuracy of a de novo model required to phase the 30 diffraction data sets
in Table 1.
Crystallographic parameter r
2 P value†
No. of modeled residues 0.592 5.7  10
4
Highest resolution reﬂection 0.232 0.22
Lowest resolution reﬂection 0.229 0.22
No. of copies in asymmetric unit 0.200 0.29
No. of reﬂections 0.146 0.44
Matthews coefﬁcient (VM) 0.095 0.62
No. of reﬂections > 4 A ˚ 0.091 0.64
No. of reﬂections > 6 A ˚ 0.079 0.68
No. of residues in asymmetric unit 0.038 0.84
Solvent content 0.022 0.91
† Correlations are to F1A ˚, the fraction of C
 atoms within 1 A ˚ of the crystal structure, of
the least accurate model that gives an unambiguous Phaser hit (see Table 1).
1 In a further test, we subjected the 50 low-resolution models with lowest C

r.m.s.d. to the crystal structure from each pool to molecular replacement in
order to estimate an upper bound on the number of successes that might be
possible if all the available models could be tested. For the low-resolution set,
this search increased the number of data sets with unambiguous Phaser
solutions from one to four. However, in both the 100 CPU day and large-scale
all-atom model sets, the number of successes increased by only one (from nine
to ten and from 15 to 16, respectively). These results indicate that for most
applications molecular-replacement trials need only to be carried out on a
limited set of the best energy models if the energies are assessed by Rosetta
all-atom reﬁnement.native protein structure after idealization of bond lengths and
bond angles. These results suggest that there are no intrinsic
artefacts in the current Rosetta all-atom force ﬁeld that
fundamentally confound molecular replacement, but that
improved conformational search methods will be required if
molecular replacement with de novo models is to become a
practical routine tool.
Overall, half of the cases tested in this benchmark could be
phased de novo using a small set of the lowest energy all-atom
models. Because approximately one third of proteins in the
tested size range appear to be predictable at high resolution
(Bradley et al., 2005; Das et al., 2007), we estimate that one
sixth of diffraction data sets for proteins with new folds and
sizes of 100 residues or less can be phased with existing
methods. We emphasize, however, that the presented
successful molecular-replacement cases have made use of
many thousands of CPU days per target made available
through distributed computing. Limiting the computational
expense from >10 000 CPU days to 100 CPU days signiﬁcantly
reduced the number of phased data sets (from 15 to nine).
Omission of the all-atom reﬁnement step led to an even more
signiﬁcant drop (from nine successes to one success). Addi-
tional strategies to explore in the future include the use of
alternative measures of phasing success beyond the Phaser
TFZ score, such as the reduction in Rfree upon likelihood-
based reﬁnement of the molecular-replacement solution
against the diffraction data (Murshudov et al., 1997), as well as
alternative processing of de novo models before phasing, such
as incorporating estimates of model uncertainty into the
Phaser likelihood calculation.
4. Tentative ‘rules of thumb’ for de novo phasing
Based on the phasing results presented so far, neither a low
solvent content nor the presence of multiple protein copies in
the asymmetric unit appears to be an insurmountable barrier
for phasing with de novo models. It may be possible, however,
that these factors or other properties of the diffraction data set
can render the phase problem more difﬁcult or more
straightforward to solve by molecular replacement. With more
than 500 Rosetta models tested in Phaser molecular replace-
ment for each of 30 diffraction data sets, this study permits an
initial exploration of factors that might correlate with the ease
with which de novo models lead to successful molecular
replacement.
We estimated this ease of phasing for each diffraction data
set by assessing the minimal model accuracy F1A ˚ required to
achieve a signiﬁcant TFZ score and correct orientation of the
model in the unit cell (see above). These estimates (Table 1)
are intrinsically noisy, since for many diffraction data sets only
a few models were found to give successful Phaser hits.
However, these minimal F1A ˚ values provide useful initial
estimates to search for the strongest (and thus most practically
useful) correlations of crystal parameters with the ease of
phasing.
Table 2 lists the correlations of these minimal F1A ˚ values
with ten parameters associated with the crystallographic data
sets, from the number of reﬂections available to the resolution
of the diffraction data to the solvent content of the data. No
correlation was detected between higher solvent content and
easeof phasing (Fig.2a). For example,the benchmark includes
four diffraction data sets for ubiquitin, in which the same pool
of Rosetta models was tested for phasing, and the data set with
the lowest solvent content (PDB code 1ubq) was the only one
for which a de novo model gave a successful Phaser solution.
Further, there was no correlation of ease of phasing with the
number of molecules in the asymmetric unit (Fig. 2b); as noted
above, use of the next-generation Phaser may in fact soon
further ease the conﬁdent and rapid phasing of crystals with
multi-copy asymmetric units.
Of the other parameters tested (Table 2), only one, the
molecular weight of the monomer, gave a statistically signiﬁ-
cant correlation (P <1 0
1) with minimal F1A ˚ values (Fig. 2c).
Larger macromolecules give crystals that are easier to phase
(P <5 . 7 10
4). As was pointed out by Randy Read
(personal communication) in an informal discussion, more
low-resolution data are available for each molecule for
constraining its rotation and translation in the unit cell.
research papers
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Figure 2
Dependence of de novo phasing on crystallographic parameters. The ease of phasing is estimated as the minimal accuracy required for successful
molecular replacement (minimum F1A ˚, the fraction of C
 atoms within 1 A ˚ of the crystal structure). No correlation is observed with the crystal solvent
content (a) or the number of molecules in each asymmetric unit (b), but a statistically signiﬁcant correlation is found with the number of residues in the
molecular-replacement model (c). See also Table 2.Indeed, the correlation of more straightforward molecular
replacement with larger macromolecules is abundantly illu-
strated by other articles in this issue, with the successful
phasing of the ribosome, the fatty-acid synthase complex
(Jenni & Ban, 2009) and other massive complexes with partly
accurate low-resolution models. In our case, as the confor-
mational search in de novo modeling becomes (exponentially)
more difﬁcult with protein length, it is gratifying that
successful molecular replacement may require somewhat less
accurate models for longer chains.
5. Summary and prospects
Molecular replacement with de novo models of protein
structures is a potentially useful new tool for phasing
diffraction data sets for which experimental phasing has failed
and structural homologs cannot be identiﬁed from sequence
alone. In this study, we have explored the necessity of all-atom
reﬁnement of de novo models, the general rate of success of
this de novo phasing method and the properties of a diffrac-
tion data set that aid or complicate the method.
Firstly, all-atom reﬁnement of coarse-grained Rosetta
models and the application of increasing computational power
appear to signiﬁcantly bolster both model quality and
performance in Phaser molecular replacement. Secondly, we
have presented 15 new cases of diffraction data sets for a wide
range of protein folds that have been phased by de novo
models. These results suggest that approximately one sixth of
existing diffraction data sets for small-sized proteins of new
folds may be phased with current algorithms if a large amount
of computational power is available. Finally, the ease of
phasing appears to be poorly correlated with the crystal
solvent content or the number of molecules in the asymmetric
unit, but is correlated with molecular weight: larger proteins
require somewhat less accurate models for successful mole-
cular replacement. As the conformational search for Rosetta
modeling improves or is aided by limited additional experi-
mental information (from, for example, NMR chemical shifts;
see Cavalli et al., 2007; Shen et al., 2008), molecular replace-
ment with de novo models can perhaps join molecular
replacement with structural homologues as a practical tool for
phasing protein diffraction data sets.
The utility of phasing with de novo models will be best
demonstrated by cases in which blind predictions provide
molecular-replacement solutions for diffraction data that have
not been phased by other means. We are currently collabor-
ating with structural genomics initiatives and traditional
biology laboratoriess in an effort to identify and solve such
data sets. In the meanwhile, a posteriori crystallographic
phasing continues to be a powerful and stringent test of de
novo modeling algorithms.
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